Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture
Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...
GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results
China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues...
Bristol Myers Squibb Enhances CAR-T Manufacturing with Cellares Platform, Securing Exclusive Access
Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has secured a deal with Cellares, a...
Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as...
China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration
The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...
MSD Strikes Deal with GV20 Therapeutics to Test Anti-PD-1 Combo in Solid Tumor Therapies
Merck, Sharp & Dohme (MSD; NYSE: MRK), a global healthcare leader, has entered into a...
Jiangsu Hengrui’s SHR-A2102 Earns FDA Fast Track Status for Urothelial Carcinoma Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
Hengrui Pharmaceuticals Gets Green Light from NMPA for Two Anti-Cancer Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Bayer CEO Joins German Chancellor on China Visit, Announces New Investments
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a multinational pharmaceutical and life sciences company...
GSK’s Gepotidacin Shows Non-Inferior Efficacy in Phase III Gonorrhoea Tria
GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK), a leading UK pharmaceutical company, last week announced positive...
Joincare Pharmaceutical’s TG-1000 Shows Promise in Phase III Flu Treatment Trial
Joincare Pharmaceutical Group Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has reportedly completed the...
Kind Pharmaceuticals Resolves Trade Secrets Dispute with Fibrogen Amid HIF-PHI Pipeline Development
Kind Pharmaceuticals LLC, a Sino-US pharmaceutical company, along with its Chinese affiliate Hangzhou Andao Pharmaceutical...
Roche’s Alecensa approved by FDA as First ALK Inhibitor for Adjuvant Treatment of NSCLC
Roche Holding AG (SWX: ROG; OTCMKTS: RHHBY), a Swiss multinational healthcare company, announced last week...
Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease
The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK),...
CareRay Digital Medical Invests $15 Million for Stake in X-Ray Detector Maker ISID
CareRay Digital Medical Technology Co., Ltd, a leading medical technology company based in Jiangsu, has...
China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders
Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based...
Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs
Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD...
Beijing Sanbo Hospital and AGE Dr. Hospital Management Group Join Forces in Brain Disease Care
Beijing Sanbo Hospital Co., Ltd, a prominent healthcare provider in China, has entered into a...
Guangzhou LBP Earns NMPA Nod for HER2 Detection Reagent to Guide Breast Cancer Treatment
Guangzhou LBP Medicine Science & Technology Co., Ltd (SHA: 688393), a biopharmaceutical company based in...
Sichuan Biokin Gets NMPA Green Light for BL-B01D1 ADC in NSCLC Clinical Trial
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a leading biopharmaceutical company based in China, has...